A Phase 4 interventional study of iStent and latanoprost/timolol in Eye Diseases, Glaucoma, Open-Angle and Glaucoma, sponsored by Glaukos Corporation. Completed at 16 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-20.
Sponsored by Glaukos Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing latanoprost in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. Latanoprost · Glaucoma, Open-Angle.
Among the 40 studies testing latanoprost in Glaucoma, Open-Angle, this one is the 15th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2009, is one of 15 in phase 4, and was the 21st registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →None of the 40 studies testing latanoprost in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →
Latanoprost: first FDA approval 1996 (XALATAN), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 117 across the 39 interventional studies. Of the 34 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 40 have an industry lead sponsor. The 10 most frequent:
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
43 studies in Glaucoma, Open-Angle by Glaukos Corporation: 7 open now, 10 under way, 2 of them phase 3. Of 30 finished, 8 (27%) have results posted.
Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is the 12th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2009, is one of 12 in phase 4, and was the 7th registered.
Glaukos Corporation’s Glaucoma, Open-Angle studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing latanoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Glaukos Corporation’s 43 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective, unmasked, randomized evaluation of the iStent in patients with primary open-angle glaucoma. Patients will be randomized to one of two groups: 1) iStent, or 2) medication.
Two hundred patients will be enrolled in the study at up to 21 clinical sites; follow-up is through 1 year.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
This study's enrollment of 192 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Eye Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One hundred patients will be randomized to implantation of two G2 stents in at least one eye.
Device: iStent
One hundred patients will be randomized to receive a fixed combination ocular hypotensive medication.
Drug: latanoprost/timolol
iStent
Also known as: stent, Trabecular micro bypass
Drug pages: Latanoprost · Timolol
Combination latanoprost/timolol
Mean intraocular pressure (IOP)
Time frame: 1 year
The record gives a start of May 2009, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Latanoprost · Timolol